Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibition

Journal of Clinical Oncology

Volumn 20, Issue 1, 2002, Pages 110-124

  Albanell, J ^a   Rojo, F ^a   Averbuch, S ^a   Feyereislova, A ^a   Mascaro, J M ^a   Herbst, R ^a   LoRusso, P ^a   Rischin, D ^a   Sauleda, S ^a   Gee, J ^a   Nicholson, R I ^a   Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; KERATIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P27; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACNE; ADULT; AGED; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CANCER; CELL MATURATION; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; ENZYME INHIBITION; EPIDERMIS; FEMALE; HAIR FOLLICLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFUNDIBULUM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; STRATUM CORNEUM; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL MARKERS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; KERATINOCYTES; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEINS;

EID: 0036139727     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.1.110     Document Type: Article

References (62)

1. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells
2. Autocrine interaction between TGF alpha and the EGF-receptor: Quantitative requirements for induction of the malignant phenotype
3. Epidermal growth factor-related peptides and their receptors in human malignancies
4. Strain-dependent epithelial defects in mice lacking the EGF receptor
5. Targeted disruption of mouse EGF receptor: Effect of genetic background on mutant phenotype
6. Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor
7. Biochemical and clinical implications of ErbB/HR signaling network of growth factor receptors
8. Regulation of signal transduction and signal diversity by receptor oligomerization
9. Requirement for intrinsic protein tyrosine kinase in the immediate and late actions of the EGF receptor
10. 6-Amino-4(3-methyl-phenylamino)-quinazoline: An EGF receptor tyrosine kinase inhibitor with activity in a range of human tumour xenografts
11. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development
12. ZD1839 (Iressa) a selective epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TK): Inhibition of c-fos MRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition
13. Antitumor effect and potentiation of cytotoxic drug activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
14. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase
15. ZD1839 (Iressa) as an anticancer agent
16. New therapeutic agents targeting the epidermal growth factor receptor
17. A Bcr/Abl Kinase antagonist for chronic myelogenous leukemia: A promising path for progress emerges
18. In vivo eradication of human Bcr/Abl-positive leukemia cells with an Abkinase inhibitor
19. Lessons learned from the development of an Abtyrosine kinase inhibitor for chronic myelogenous leukemia
20. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C 225 alone and in combination with cisplatin
21. Immunolocalization of epidermal growth factor receptors in normal developing human skin
22. The EGF receptor: An essential regulator of multiple epidermal functions
23. The epidermal growth factor receptor is required to maintain the proliferative population in the basal compartment of epidermal tumors
24. Stem cell patterning and fate in human epidermis
25. Anatomy and organization of human skin
26. Epidermal differentiation and keratin gene expression
27. Involvement of follicular stem cells in forming not only the follicle but also the epidermis
28. Epidermal growth factor receptor-dependent control of keratinocyte survival and Bc-xL expression through a MEK-dependent pathway
29. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal differentiation
30. EGF receptor signaling inhibits keratinocyte apoptosis: Evidence for mediation by Bc-XL
31. TGF alpha deficiency results in hair follicle and eye abnormalities in targeted and waved-1 mice
32. The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase
33. Mice with a null mutation of the TGF alpha gene have abnormal skin architecture, wavy hair, and curly whiskers and often develop corneal inflammation
34. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation
35. Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types: Evidence of activity and good tolerabilit
36. Phase I dose escalation study of epidermal growth factor tyrosine kinase inhibitor CP-358774 in patients with advanced solid tumors
37. Dose and scheduleduration escalation of the epidermal growth factor receptor tyrosine kinase inhibitor CP-358774: A phase I and pharmacokinetic study
38. Immunodetection of the ligand-activated receptor for the epidermal growth factor
39. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
40. New EGF-R selective tyrosine kinase inhibitor reveals variable growth responses in prostate carcinoma cell lines PC-3 and DU-145
41. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
42. Immunocytochemical localization of Shand activated EGF receptor in early endosomes after EGF stimulation of HeLa cells
43. All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired
44. Catalyzed reporter deposition, a novel method of signal amplification: Application to immunoassays
45. Keratinocyte growth factor receptor ligands induce transforming growth factor alpha expression and activate the epidermal growth factor receptor signaling pathway in cultured epidermal keratinocytes
46. Signal transduction through MAP kinase cascades
47. Activation of mitogenactivated protein kinase is associated with epidermal growth factor receptor, transforming growth factor alpha and HER2 receptor overexpression in head and neck tumors
48. Blockade of the EGF receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGFα bigenic mice
49. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections
50. High telomerase activity in primary lung cancers: Association with increased cell proliferation rates and advanced pathologic stage
51. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development
52. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity
53. KiP1 inducing G1 arrest and enhancing the antitumor effect of Interferon alpha
54. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
55. STAT3 activation accompanies keratinocyte differentiation
56. Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes
57. Inhibitors of tyrosine kinases in the treatment of psoriasis
58. Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors
59. ZD1839 (Iressa), an oral EGFR-TKI (epidermal growth factor tyrosine kinase inhibitor): Pharmacokinetics in a phase I study of patients with advanced cancer
60. Biological and clinical associations of c-jun activation in human breast cancer
61. Phosphorylation of ERK1/2 mitogen activated protein kinase is associated with poor response to antihormonal therapy and decreased patient survival in clinical breast cancer
62. Characterization of epidermal growth factor (EGF) receptor and transforming growth factor (TGF)-alpha expression in gastric cancer and its association with activation of mitogen-activated protein kinase (MAPK)